Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07781930

Comparison of Transversus Abdominis Plane and Erector Spinae Plane Blocks for Pain Control After Renal Laparoscopy

The goal of this study is to compare the analgesic efficacy of ultrasound-guided transversus abdominis plane (TAP) block versus erector spinae plane block (ESPB) in adult patients undergoing laparoscopic renal surgeries. Forty adults (18-60 years, ASA I-II) will be randomly assigned to receive either TAP or ESPB after induction of general anesthesia. Postoperative pain will be assessed using the Visual Analogue Scale (VAS) and total fentanyl consumption over 24 hours. Secondary outcomes include time to first analgesic request, hemodynamic parameters, patient satisfaction, and incidence of complications. The study will be conducted at Cairo University Hospitals following ethical approval, with all patients providing written informed consent.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kasr Al-Ainy hospital

Cairo, 11562, Egypt

Location status: Recruiting

Location contact

Hala ElSabbagh, M.D.

CONTACT

[email protected]

01005207896

About this study

This randomized controlled trial aims to compare the analgesic efficacy of ultrasound-guided transversus abdominis plane (TAP) block versus erector spinae plane block (ESPB) in adult patients undergoing laparoscopic renal surgeries. Forty adults (18-60 years, ASA I-II) will be randomly assigned to receive either TAP or ESPB after induction of general anesthesia.

Preoperative assessment will include medical and surgical history, clinical examination, and routine laboratory investigations.

Intraoperative management will follow standard monitoring with general anesthesia, and the block will be performed under ultrasound guidance using 0.25% bupivacaine, bilaterally. TAP block will be performed at the anterolateral abdominal wall, while ESPB will be performed at the T8-T9 level in lateral decubitus position. The anesthesiologist performing the block will not participate in postoperative data collection, and outcome assessors will be blinded.

Postoperative pain management includes IV paracetamol every 8 hours and rescue fentanyl boluses (25 μg IV) if VAS ≥4, with a maximum total dose of 0.2-0.4 mg in 24 hours. Pain will be measured using the Visual Analogue Scale (VAS) at PACU, 2, 4, 6, 12, 18, and 24 hours. Secondary outcomes include time to first analgesic request, hemodynamic parameters, patient satisfaction, and incidence of adverse events such as PONV, hypotension, bradycardia, urinary retention, LAST, pneumothorax, or failed block.

Primary outcome: total fentanyl consumption in the first 24 hours postoperatively.

Secondary outcomes: time to first rescue analgesia, VAS scores, hemodynamic stability, patient satisfaction, and complications. The study will be conducted at Cairo University Hospitals after ethical committee approval, with all patients providing written informed consent. Data will be analyzed using SPSS v26, with parametric and non-parametric tests, repeated-measures ANOVA for VAS over time, Kaplan-Meier analysis for time to rescue analgesia, and chi-square or Fisher's exact test for categorical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 40 years old.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I, II.
  • Scheduled for laparoscopic renal surgeries under general anesthesia

Exclusion criteria

  • Parent's refusal.
  • Coagulation disorders.
  • History of allergy to local anesthetics.
  • Infection or redness at the injection site.
  • History of renal and/or hepatic insufficiency.
  • Preexisting cardiac dysfunction.

Treatment and study plan

TAP Block

Procedure

a bilateral ultrasound guided TAP block performed by injecting 20 ml of 0.25% bupivacaine into the TAP space after negative aspiration.

a bilateral ultrasound guided ESP block performed by injecting 20 ml of 0.25% bupivacaine into the ESP space after negative aspiration.

Other names: ESP Block

Primary outcomes

  1. Total fentanyl consumption.

    Time frame: 24 hours.

    Total fentanyl consumption in the first 24 hours (μg-microgram) postoperative.

Secondary outcomes

  1. Time to first rescue analgesia.

    Time frame: 24 hours postoperatively.

    Time elapsed from the end of surgery until the patient requires the first dose of rescue analgesia.

  2. Postoperative Pain scores.

    Time frame: At Post Anesthesia Care Unit (PACU) and 2,4,6,12,18,24 hours Postoperatively.

    pain assessment using Visual Analog Scale (VAS) score: pain level scored from 0 (no pain) to 10 (worst imaginable pain).

  3. Hemodynamic Parameter Heart rate

    Time frame: At PACU and 1,2,4,6,12,24 hours postoperatively.

    Heart rate

  4. Hemodynamic Parameter

    Time frame: At PACU and 1,2,4,6,12,24 hours postoperatively.

    mean arterial blood pressure

  5. Hemodynamic Parameter oxygen saturation

    Time frame: At PACU and 1,2,4,6,12,24 hours postoperatively.

    oxygen saturation

  6. Patient Satisfaction.

    Time frame: 24 hours postoperatively.

    Degree of patients' satisfaction.

  7. Incidence of postoperative complications.

    Time frame: within 24 hours postoperatively.

    Incidence of complications as hypotension, bradycardia, respiratory depression, pneumothorax and urine retention.

Study contacts

Contact information is provided by the study sponsor or research team.

Hala ElSabbagh, M.D.

CONTACT

[email protected]

01005207896

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Comparison of Ultrasound-guided Transversus Abdominis Plane Block (TAP) and Erector Spinae Plane Block (ESPB) for Postoperative Analgesia in Adult Laparoscopic Renal Surgeries: A Randomized Controlled Trial.

Acronym: TAP-ESPB

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 24, 2026
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.